{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T00:08:01Z","timestamp":1717286881212},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"am","delay-in-days":395,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.therap.2023.07.004","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T21:28:24Z","timestamp":1690579704000},"page":"379-392","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Un outil d\u2019adaptation individualis\u00e9e des posologies de m\u00e9dicaments chez le patient adulte ob\u00e8se"],"prefix":"10.1016","volume":"79","author":[{"given":"Julien","family":"Gouju","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Jourdan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Legeay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2023.07.004_bib0165","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1016\/S0140-6736(17)32129-3","article-title":"Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2,416 population-based measurement studies in 1,289 million children, adolescents, and adults","volume":"390","author":"Abarca-G\u00f3mez","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2023.07.004_bib0170","series-title":"Enqu\u00eate \u00e9pid\u00e9miologique nationale sur le surpoids et l\u2019ob\u00e9sit\u00e9","author":"Odoxa","year":"2021"},{"key":"10.1016\/j.therap.2023.07.004_bib0175","series-title":"\u00c9tude de sant\u00e9 sur l\u2019environnement, la biosurveillance, l\u2019activit\u00e9 physique et la nutrition (Esteban), 2014\u20132016. Volet Nutrition. Chapitre Corpulence","author":"Sant\u00e9 Publique France","year":"2017"},{"key":"10.1016\/j.therap.2023.07.004_bib0180","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/phar.2023","article-title":"Comprehensive guidance for antibiotic dosing in obese adults","volume":"37","author":"Meng","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.therap.2023.07.004_bib0185","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/cob.12076","article-title":"Antibiotic dosing in obesity: the search for optimum dosing strategies: antibiotic dosing in obesity","volume":"4","author":"Tucker","year":"2014","journal-title":"Clin Obes"},{"key":"10.1016\/j.therap.2023.07.004_bib0190","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2125.2004.02157.x","article-title":"What is the best size descriptor to use for pharmacokinetic studies in the obese?","volume":"58","author":"Green","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2023.07.004_bib0195","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ijantimicag.2016.01.009","article-title":"Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: a structured review","volume":"47","author":"Alobaid","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.therap.2023.07.004_bib0200","doi-asserted-by":"crossref","first-page":"189","DOI":"10.18773\/austprescr.2017.053","article-title":"Drug dosing in obese adults","volume":"40","author":"Barras","year":"2017","journal-title":"Aust Prescr"},{"key":"10.1016\/j.therap.2023.07.004_bib0205","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2165\/00003088-200038050-00003","article-title":"Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics","volume":"38","author":"Bearden","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.therap.2023.07.004_bib0210","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003088-200039030-00004","article-title":"Effects of obesity on pharmacokinetics: implications for drug therapy","volume":"39","author":"Cheymol","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.therap.2023.07.004_bib0215","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00134-003-2059-6","article-title":"Dosing of medications in morbidly obese patients in the intensive care unit setting","volume":"30","author":"Erstad","year":"2004","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.therap.2023.07.004_bib0220","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jcrc.2012.11.018","article-title":"Dose modulation: a new concept of antibiotic therapy in the critically ill patient?","volume":"28","author":"Goncalves-Pereira","year":"2013","journal-title":"J Crit Care"},{"key":"10.1016\/j.therap.2023.07.004_bib0225","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/QCO.0000000000000356","article-title":"Obesity and skin and soft tissue infections: how to optimize antimicrobial usage for prevention and treatment?","volume":"30","author":"Grupper","year":"2017","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.therap.2023.07.004_bib0230","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/QCO.0b013e328359a4c1","article-title":"Dosing of antibiotics in obesity","volume":"25","author":"Janson","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.therap.2023.07.004_bib0235","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1592\/phco.27.8.1081","article-title":"Antimicrobial dosing considerations in obese adult patients: insights from the Society of Infectious Diseases Pharmacists","volume":"27","author":"Pai","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.therap.2023.07.004_bib0240","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/jcpt.12200","article-title":"Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review","volume":"39","author":"Polso","year":"2014","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.therap.2023.07.004_bib0245","doi-asserted-by":"crossref","first-page":"e224","DOI":"10.1097\/MJT.0000000000000401","article-title":"Influence of morbid obesity on the clinical pharmacokinetics of various anti-infective drugs: reappraisal using recent case studies-issues, dosing implications, and considerations","volume":"25","author":"Srinivas","year":"2018","journal-title":"Am J Ther"},{"key":"10.1016\/j.therap.2023.07.004_bib0250","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1086\/514505","article-title":"Antimicrobial dosing in obese patients","volume":"25","author":"Wurtz","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.therap.2023.07.004_bib0255","series-title":"Le bon usage clinique du m\u00e9dicament","author":"SiteGPR","year":"2022"},{"key":"10.1016\/j.therap.2023.07.004_bib0260","series-title":"Endocardite.org. Calcul de posologie chez les ob\u00e8ses","year":"2022"},{"key":"10.1016\/j.therap.2023.07.004_bib0265","first-page":"e123","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"3","author":"Moher","year":"2009","journal-title":"Open Med"},{"key":"10.1016\/j.therap.2023.07.004_bib0270","series-title":"Qu\u2019est-ce que Lumen \u2013 Le framework Micro Laravel?","year":"2022"},{"key":"10.1016\/j.therap.2023.07.004_bib0275","series-title":"An extensive math library for JavaScript and Node. js","author":"math.js","year":"2022"},{"key":"10.1016\/j.therap.2023.07.004_bib0280","series-title":"World Health Organization. Obesity: preventing and managing the global epidemic","first-page":"267","author":"WHO","year":"2000"},{"key":"10.1016\/j.therap.2023.07.004_bib0285","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1345\/aph.19381","article-title":"The origin of the \u00ab\u00a0ideal\u00a0\u00bb body weight equations","volume":"34","author":"Pai","year":"2000","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.therap.2023.07.004_bib0290","first-page":"650","article-title":"Gentamicin therapy","volume":"8","author":"Devine","year":"1974","journal-title":"Drug Intell Clin Pharm"},{"key":"10.1016\/j.therap.2023.07.004_bib0295","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/j.1875-9114.2012.01108.x","article-title":"Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults","volume":"32","author":"Pai","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.therap.2023.07.004_bib0300","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.bbmt.2014.01.019","article-title":"Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation Practice Guideline Committee","volume":"20","author":"Bubalo","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.therap.2023.07.004_bib0305","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/j.bulcan.2017.07.010","volume":"104","author":"Simon","year":"2017","journal-title":"Bull Cancer"},{"key":"10.1016\/j.therap.2023.07.004_bib0310","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/phar.1156","article-title":"Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review","volume":"33","author":"Davies-Vorbrodt","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.therap.2023.07.004_bib0315","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1093\/jac\/dks312","article-title":"Evaluation of the effect of obesity on voriconazole serum concentrations","volume":"67","author":"Koselke","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.therap.2023.07.004_bib0160","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/11599410-000000000-00000","article-title":"Impact of obesity on drug metabolism and elimination in adults and children","volume":"51","author":"Brill","year":"2012","journal-title":"Clinical Pharmacokinet"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595723001051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595723001051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T05:39:32Z","timestamp":1717220372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595723001051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0040595723001051"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2023.07.004","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Un outil d\u2019adaptation individualis\u00e9e des posologies de m\u00e9dicaments chez le patient adulte ob\u00e8se","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2023.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}